Player FM - Internet Radio Done Right
Checked 1M ago
Added nine years ago
Content provided by Taylor & Francis Group and Francis Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Taylor & Francis Group and Francis Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
The need for HRMS for quantitation of ADCs vs. QQQ: an interview with Megan Cooley
Manage episode 460395649 series 1258384
Content provided by Taylor & Francis Group and Francis Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Taylor & Francis Group and Francis Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In this episode, we sit down with Megan Cooley, Associate Director of Bioanalytical Services at ICON (KS, USA), to explore the cutting-edge world of antibody-drug conjugate (ADC) quantitation using high-resolution mass spectrometry (HRMS). Megan delves into the capabilities of Triple Quadrupole and Time-of-Flight mass spectrometry, offering her expert insights into whether HRMS is essential for ADC PK studies. We also tackle the challenges and limitations of HRMS in ADC quantitation and discuss the potential for AI to create more specific and stable ADCs. Finally, Megan highlights ICON’s extensive experience with large molecule applications and their innovative approach to supporting complex LC–MS analyses.
…
continue reading
290 episodes
Manage episode 460395649 series 1258384
Content provided by Taylor & Francis Group and Francis Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Taylor & Francis Group and Francis Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In this episode, we sit down with Megan Cooley, Associate Director of Bioanalytical Services at ICON (KS, USA), to explore the cutting-edge world of antibody-drug conjugate (ADC) quantitation using high-resolution mass spectrometry (HRMS). Megan delves into the capabilities of Triple Quadrupole and Time-of-Flight mass spectrometry, offering her expert insights into whether HRMS is essential for ADC PK studies. We also tackle the challenges and limitations of HRMS in ADC quantitation and discuss the potential for AI to create more specific and stable ADCs. Finally, Megan highlights ICON’s extensive experience with large molecule applications and their innovative approach to supporting complex LC–MS analyses.
…
continue reading
290 episodes
All episodes
×F
Future Science Group

1 Unveiling bioanalytical datasets for the successful development of ADCs 19:03
19:03
Play Later
Play Later
Lists
Like
Liked19:03
Unveiling bioanalytical datasets for the successful development of ADCs
F
Future Science Group

1 Bridging science and safety: exploring toxicology studies and regulatory requirements 10:50
10:50
Play Later
Play Later
Lists
Like
Liked10:50
Bridging science and safety: exploring toxicology studies and regulatory requirements
F
Future Science Group

1 Cell therapies for autoimmune diseases: a podcast with Lindsay Davies 13:17
13:17
Play Later
Play Later
Lists
Like
Liked13:17
This International Women’s Day, we’re joined by Lindsay Davies, Chief Scientific Officer at NextCell Pharma (Stockholm, Sweden), to discuss the evolving role of cell therapies in treating autoimmune diseases. In this podcast, Davies breaks down the science behind NextCell’s mesenchymal stromal cell therapy for type 1 diabetes and explores how these cells could be applied to other autoimmune conditions. She emphasizes the importance of tailoring cell therapies based on disease type, stage and patient profile to achieve the best outcomes. The conversation also highlights how growing evidence of sex-related differences will could increasingly shape decisions in the development and testing of cell therapies.…
F
Future Science Group

1 The use of GenAI in bioanalysis: an interview with Priyata Kalra 28:30
28:30
Play Later
Play Later
Lists
Like
Liked28:30
During the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 2024 conference, Bioanalysis Zone caught up with industry experts across numerous disciplines to discuss their involvement with AAPS and their research. In this interview, we spoke to Priyata Kalra about her talk on the use of GenAI within biomedicine.…
F
Future Science Group

1 The need for HRMS for quantitation of ADCs vs. QQQ: an interview with Megan Cooley 21:35
21:35
Play Later
Play Later
Lists
Like
Liked21:35
In this episode, we sit down with Megan Cooley, Associate Director of Bioanalytical Services at ICON (KS, USA), to explore the cutting-edge world of antibody-drug conjugate (ADC) quantitation using high-resolution mass spectrometry (HRMS). Megan delves into the capabilities of Triple Quadrupole and Time-of-Flight mass spectrometry, offering her expert insights into whether HRMS is essential for ADC PK studies. We also tackle the challenges and limitations of HRMS in ADC quantitation and discuss the potential for AI to create more specific and stable ADCs. Finally, Megan highlights ICON’s extensive experience with large molecule applications and their innovative approach to supporting complex LC–MS analyses.…
F
Future Science Group

1 How can medical device regulation catch up with innovation? 12:36
12:36
Play Later
Play Later
Lists
Like
Liked12:36
In this interview, we discuss the potential of AI in increasing healthcare system efficiency, how medical devices are making procedures less invasive and what those working in the field of medical devices can do to help regulation catch up with innovation.
F
Future Science Group

1 The new frontier: assessing efficacy and safety of CGTs using biomarkers 24:21
24:21
Play Later
Play Later
Lists
Like
Liked24:21
In the sixth episode of The new frontier podcast, we're joined by Catherine Vrentas, Life Sciences Lead at Booz Allen Hamilton (VA, USA). Cathy explains how biomarkers can be used to predict the therapeutic outcome and efficacy of CGTs and the biomarkers in particular that have shown strong predictive value. We delve into the common challenges of working with biomarkers in CGTs and how biomarker kits can be adapted for CGT work.…
F
Future Science Group

Carlon Fitzpatrick AI Summit by Taylor & Francis Group
F
Future Science Group

1 Challenges and solutions in monitoring assay performance for vaccine development 18:26
18:26
Play Later
Play Later
Lists
Like
Liked18:26
Challenges and solutions in monitoring assay performance for vaccine development: an interview with Atul Chaudhari
F
Future Science Group

1 ADA detection and characterization for immunogenicity testing: insights from ICON's Lindsay Denhoff 11:13
11:13
Play Later
Play Later
Lists
Like
Liked11:13
We caught up with Principal Scientist Lindsay Denhoff (ICON; Dublin, Ireland) to discuss immunogenicity considerations for therapeutic proteins and the current analytical methodologies for detecting and characterizing anti-drug antibodies (ADAs). Lindsay shares some industry best practices for achieving high-quality ADA assays, as well as some of the advantages and limitations of singlicate ADA analysis compared with alternative techniques. We finish the interview with a look to the future where Lindsay discusses the emerging trends she's spotted in the field of immunogenicity and offers her predictions for how they may shape the future of therapeutic protein development.…
F
Future Science Group

In this Tech Blast episode supported by Sartorius (Göttingen, Germany), we speak with David Apiyo – Manager of Applications Development at Sartorius (MN, USA) – about epitope binning, why it's performed and the best ways to conduct it. Plus, learn more about Sartorius' biolayer interferometry platforms and their application in epitope binning.…
F
Future Science Group

1 Using the Gyrolab® platform for oligo quantification: an interview with John Chappell 6:35
6:35
Play Later
Play Later
Lists
Like
Liked6:35
In this interview, we spoke to John Chappell, Senior Global Scientific Support Manager at Gyros Protein Technologies (Uppsala, Sweden) about his experience working with the Gyrolab platform for oligonucleotide assays. John discusses the advantages of using Gyrolab for oligo quantification in biological fluids and shares his thoughts on the next steps for these assays.…
F
Future Science Group

1 The new frontier: qPCR vs ddPCR for cell and gene therapies 15:41
15:41
Play Later
Play Later
Lists
Like
Liked15:41
In the fifth episode of The New Frontier podcast, we're joined by Paul Byrne, Senior Director of Genomics from ProtaGene (MA, USA). Paul describes his experience working with qPCR vs digital and digital droplet PCR assays and advises on their pros and cons, as well as when it's best to use each. We discuss how these assays can be optimized for cell and gene therapy targets and get a peek into the tips and tricks he's picked up over his 30 years of experience.…
F
Future Science Group

1 The new frontier: using LC–MS/MS for quantitative assays to support gene therapies 13:33
13:33
Play Later
Play Later
Lists
Like
Liked13:33
In this episode of The New Frontier podcast, we're joined by Daniel Schulz-Jander, Senior Director of Mass spectrometry Bioanalysis at QPS Netherlands (Groningen). Daniel explains how he uses immune-precipitation and immunoaffinity LC–MS techniques for his work relating to macromolecular pharmaceuticals like gene therapies, as well as their benefits and challenges. Daniel also covers bottom-up, middle-down and top-down approaches and their suitability for his work in clinical support versus research and discovery.…
F
Future Science Group

1 Breaking down barriers for women in tech: an interview with Tina Marshall 16:15
16:15
Play Later
Play Later
Lists
Like
Liked16:15
Breaking down barriers for women in tech: an interview with Tina Marshall by Taylor & Francis Group
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.